Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB
Neuroscientific Biopharmaceuticals — Corporate Update (September 2022)
8 slides from Neuroscientific Biopharmaceuticals's corporate update, Sep 20, 2022
Slide 1: Investor Update
NOVEL DRUG THERAPIES FOR NEURODEGENERATIVE CONDITIONS INVESTOR UPDATE SEPTEMBER 2022 • ASX: NSB neuroscientific.com
Slide 2: Disclaimer
DISCLAIMER The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clari
Slide 3: NSB Investor Update on EmtinB HREC Submission
NSB INVESTOR UPDATE ON EMTINBTM HREC SUBMISSION neuroscientific.com • 3
Slide 4: Structural Formula of EmtinB
STRUCTURAL FORMULA OF EMTINBTM EmtinB™ is a peptide derived from Metallothionien-II neuroscientific.com • 4
Slide 5: HREC Submission Refused on Three Matters
HREC SUBMISSION REFUSED ON THREE MATTERS NSB understands the HREC decision. The HREC explained the three reasons for the refusal were safety, purity of EmtinBTM and efficacy. • Safety- local injection site tolerability was not satisfactorily demonstrated, with systemic safety not noted as a concern.
Slide 6: NSB Next Steps for EmtinB (3-6 months)
NSB NEXT STEPS FOR EMTINBTM (3-6 months) • Safety: Two independent toxicologists (one US board certified and one with both US and EU board certification) to perform a thorough GAP analysis. Following completion of all required toxicology, a formal independent toxicology report opinion will be provid
Slide 7: NSB Next Steps for EmtinB (3-6 months)
NSB NEXT STEPS FOR EMTINBTM (3-6 months) • Interim CEO: Potential to appoint an interim CEO to oversee the next 3-6 months. • Potential new asset licensed into NSB: The Company plans to file at least 2 new patents on EmtinB and potentially licensed in a new technology to expand the Company’s pipelin
Slide 8: neuroscientific.com
neuroscientific.com For more information contact: Paul Rennie– Chairman E: ir@neuroscientific.com
NeuroScientific Biopharmaceuticals — Corporate Update (September 2022) on 6ix